Evidence map›Paper›PMID 36555608›Full record

ArticleInternational journal of molecular sciences2022

Mathematical Model for Evaluation of Tumor Response in Targeted Radionuclide Therapy with

Yoshiharu Yonekura, Hiroshi Toki, Tadashi Watabe, Kazuko Kaneda-Nakashima, Yoshifumi Shirakami, Kazuhiro Ooe, Atsushi Toyoshima, Hiroo Nakajima, Noriyuki Tomiyama, Masako Bando

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yoshiharu YonekuraInstitute for Radiation Sciences, Osaka University, Suita 565-0871, Japan.ORCID 0000-0002-1211-7041
Hiroshi TokiResearch Center for Nuclear Physics, Osaka University, Suita 565-0047, Japan.ORCID 0000-0003-1332-8286
Tadashi WatabeInstitute for Radiation Sciences, Osaka University, Suita 565-0871, Japan.
Kazuko Kaneda-NakashimaInstitute for Radiation Sciences, Osaka University, Suita 565-0871, Japan.ORCID 0000-0001-6657-5059
Yoshifumi ShirakamiInstitute for Radiation Sciences, Osaka University, Suita 565-0871, Japan.ORCID 0000-0003-2352-9057
Kazuhiro OoeInstitute for Radiation Sciences, Osaka University, Suita 565-0871, Japan.
Atsushi ToyoshimaInstitute for Radiation Sciences, Osaka University, Suita 565-0871, Japan.
Hiroo NakajimaInstitute for Radiation Sciences, Osaka University, Suita 565-0871, Japan.
Noriyuki TomiyamaInstitute for Radiation Sciences, Osaka University, Suita 565-0871, Japan.ORCID 0000-0001-9918-7327
Masako BandoYukawa Institute for Theoretical Physics, Kyoto University, Kyoto 606-8502, Japan.

Funding

Research Center for Nuclear Physics, Osak University N/A
6 · The paper itself

Abstract

Recent introduction of alpha-emitting radionuclides in targeted radionuclide therapy has stimulated the development of new radiopharmaceuticals. Preclinical evaluation using an animal experiment with an implanted tumor model is frequently used to examine the efficiency of the treatment method and to predict the treatment response before clinical trials. Here, we propose a mathematical model for evaluation of the tumor response in an implanted tumor model and apply it to the data obtained from the previous experiment of

Indexed as

NeoplasmsRadiopharmaceuticalsAnimalsMiceModels, TheoreticalRadioisotopesRadioisotopesRadiopharmaceuticals211Atalpha therapymathematical modeltargeted radionuclide therapy

Identifiers

PMID36555608
PMCPMC9788218

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.